1. Home
  2. HRMY vs SAM Comparison

HRMY vs SAM Comparison

Compare HRMY & SAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

HOLD

Current Price

$37.03

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Logo Boston Beer Company Inc. (The)

SAM

Boston Beer Company Inc. (The)

HOLD

Current Price

$178.19

Market Cap

1.9B

ML Signal

HOLD

Company Overview

Basic Information
Metric
HRMY
SAM
Founded
2017
1984
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Beverages (Production/Distribution)
Sector
Health Care
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.9B
IPO Year
2020
1996

Fundamental Metrics

Financial Performance
Metric
HRMY
SAM
Price
$37.03
$178.19
Analyst Decision
Buy
Hold
Analyst Count
9
11
Target Price
$44.11
$233.70
AVG Volume (30 Days)
854.1K
282.6K
Earning Date
05-07-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
7.97
95.45
EPS
0.55
N/A
Revenue
$868,453,000.00
$1,964,994,000.00
Revenue This Year
$19.75
$1.02
Revenue Next Year
$12.88
$1.31
P/E Ratio
$67.75
N/A
Revenue Growth
21.51
N/A
52 Week Low
$25.52
$158.68
52 Week High
$40.87
$264.46

Technical Indicators

Market Signals
Indicator
HRMY
SAM
Relative Strength Index (RSI) 68.61 47.33
Support Level $35.05 $170.14
Resistance Level $39.12 $188.80
Average True Range (ATR) 1.04 6.57
MACD 0.22 1.18
Stochastic Oscillator 93.53 37.36

Price Performance

Historical Comparison
HRMY
SAM

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

About SAM Boston Beer Company Inc. (The)

Boston Beer is a top player in high-end malt beverages and adjacent categories in the US, with strong positions in craft beer, flavored malt beverages, hard cider, and hard seltzer. The bulk of volume and revenue is concentrated in four brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly. Beverages are produced using a hybrid model leveraging both in-house capacities and third-party breweries through contract arrangements. While the firm is required to use distributors to reach end markets, including retailers and on-premises operators, it also employs 500 internal sales representatives to educate the market about its products. The firm generates almost all sales in the US.

Share on Social Networks: